No abstract available
MeSH terms
-
Animals
-
Antibiotics, Antineoplastic / administration & dosage
-
Antibiotics, Antineoplastic / adverse effects
-
Antibiotics, Antineoplastic / chemistry
-
Antibiotics, Antineoplastic / pharmacology*
-
Antibiotics, Antineoplastic / therapeutic use
-
Antibodies, Monoclonal / adverse effects
-
Antibodies, Monoclonal / chemistry
-
Antibodies, Monoclonal / immunology
-
Antibodies, Monoclonal / pharmacology*
-
Antibodies, Monoclonal / therapeutic use
-
Antigens, Neoplasm / immunology*
-
Carcinoma / drug therapy
-
Carcinoma / immunology*
-
Clinical Trials, Phase I as Topic
-
Colonic Neoplasms / drug therapy
-
Daunorubicin / chemistry
-
Daunorubicin / pharmacology
-
Digestive System / immunology
-
Doxorubicin / adverse effects
-
Doxorubicin / chemistry
-
Doxorubicin / immunology
-
Doxorubicin / pharmacology*
-
Doxorubicin / therapeutic use
-
Drug Design
-
Gastrointestinal Diseases / chemically induced
-
Humans
-
Immunotoxins / adverse effects
-
Immunotoxins / chemistry
-
Immunotoxins / pharmacology*
-
Immunotoxins / therapeutic use
-
Lewis Blood Group Antigens / immunology*
-
Mice
-
Mice, Nude
-
Neoplasms / drug therapy
-
Neoplasms, Experimental / drug therapy
-
Organ Specificity
-
Rats
-
Rats, Inbred BN
-
Rats, Nude
-
Treatment Failure
-
Xenograft Model Antitumor Assays
Substances
-
Antibiotics, Antineoplastic
-
Antibodies, Monoclonal
-
Antigens, Neoplasm
-
BR96-doxorubicin immunoconjugate
-
Immunotoxins
-
Lewis Blood Group Antigens
-
Lewis Y antigen
-
Doxorubicin
-
Daunorubicin